{
    "clinical_study": {
        "@rank": "94190", 
        "arm_group": [
            {
                "arm_group_label": "Concomitant Levaquin, Ethambutol, Azithromycin and Rifampin", 
                "arm_group_type": "Active Comparator", 
                "description": "Levofloxacin 500mg po QD; Ethambutol 1200mg po QD; Azithromycin 250 mg po QD; Rifampin 600mg po QD or Rifabutin 300mg po QD"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Riboflavin will be used for rifampin; encapsulated microcrystalline cellulose will be used to replace the levofloxacin, ethambutol and azithromycin.\nThe pill count will be the same as the comparator regimen."
            }
        ], 
        "brief_summary": {
            "textblock": "The primary purpose of this study is to investigate the efficacy and safety of oral\n      antimycobacterial therapy in patients with confirmed progressive pulmonary sarcoidosis.  We\n      suspect that the CLEAR regimen will improve the absolute FVC percent predicted in chronic\n      pulmonary sarcoidosis participants."
        }, 
        "brief_title": "Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis", 
        "completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Sarcoidosis; Antimycobacterial Therapy;", 
        "condition_browse": {
            "mesh_term": [
                "Sarcoidosis", 
                "Sarcoidosis, Pulmonary"
            ]
        }, 
        "detailed_description": {
            "textblock": "Primary Objective:  To assess the efficacy and safety of oral CLEAR therapy in patients with\n      confirmed progressive pulmonary sarcoidosis.\n\n      Hypothesis: The CLEAR regimen will improve the absolute FVC percent predicted in chronic\n      pulmonary sarcoidosis participants by augmenting T cell responses through the normalization\n      of p56Lck expression and IL-2 production."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with sarcoidosis as defined by the ATS/ERS/WASOG statement on sarcoidosis as\n             defined by the clinical presentation consistent with sarcoidosis, as well as biopsy\n             demonstrating granulomas, and no alternative for the cause of the granulomas, such as\n             tuberculosis for at least one year prior to randomization.  Tuberculosis must be\n             ruled out by negative histology and culture.\n\n          -  Diagnosis of pulmonary sarcoidosis was made at least 1 year prior to consent date.\n\n          -  Evidence of disease progression as defined by at least two of the following four\n             criteria:\n\n               1. Decline of absolute percent predicted of FVC (FVC>45% and <=90% of predicted\n                  value) or DLCO of at least 5% on serial measurements (DLCO range >35%, if\n                  measured);\n\n               2. Radiographic progression in chest imaging on side by side comparison;\n\n               3. Change in dyspnea score, as measured by Transition Dyspnea Index (TDI);\n\n               4. Progression of pulmonary sarcoidosis necessitating an increase in\n                  anti-sarcoidosis therapy.\n\n          -  Positive peripheral immune responses to ESAT-6 as a biomarker of response to CLEAR\n             regimen.\n\n          -  Possess evidence of parenchymal or nodal disease on chest radiograph.\n\n        Exclusion Criteria:\n\n          -  \u2022 Inability to obtain consent\n\n               -  Age less than 18 years of age\n\n               -  If female, participant is either not of childbearing potential, defined as\n                  postmenopausal for at least 1 year or surgically sterile (bilateral tubal\n                  ligation, bilateral oophorectomy, or hysterectomy), or is using one of the\n                  following methods of birth control for the duration of the study and 90 days\n                  after study completion: condoms, sponge, foams, jellies, diaphragm, or\n                  intrauterine device or a vasectomized sole partner.  Note: Oral contraceptive\n                  pills are not effective birth control when taking rifampin or rifabutin.\n                  Females of childbearing potential must have a negative urine pregnancy test at\n                  screening visit\n\n               -  End-stage fibrotic pulmonary disease\n\n               -  Significant underlying liver disease\n\n               -  Poor venous access for obtaining blood samples\n\n               -  History of active tuberculosis, close contact with a person with active\n                  tuberculosis within the 6 months prior to the screening visit or has a positive\n                  PPD.\n\n               -  Significant disorder, other than sarcoidosis, that would complicate the\n                  treatment evaluation, such as respiratory, cardiac, neurologic, musculoskeletal\n                  or seizure disorders\n\n               -  Use of an investigational drug within 30 days prior to screening or within 5\n                  half-lives of the agent, whichever is longer.\n\n               -  Currently receiving >40mg prednisone.\n\n               -  ALT or AST \u22655 times upper limit of normal (ULN)\n\n               -  Leukopenia, as defined by WBC <3.0 cells/mm3 or absolute neutrophil count <1000\n                  mm3\n\n               -  Breast feeding.\n\n               -  Color perception impairment as defined by the inability to differentiate colors\n                  per personal history or history of optic neuritis from any cause, including from\n                  sarcoidosis.\n\n               -  Family or personal history of long QT interval\n\n               -  Most recent nuclear medicine scan or echocardiogram (if done), demonstrating\n                  cardiac ejection fraction <35%\n\n               -  If patient is on immunomodulators, they must be on regimen for \u22653-month period\n                  and on a stable dose for \u2265 4 weeks.\n\n               -  Participant has persistent or active infections requiring hospitalization or\n                  treatment with IV antibiotics, IV antiretrovirals, or IV antifungals within 30\n                  days of baseline, OR oral antibiotics, antivirals, or antifungals for purpose of\n                  treating infection, within 14 days of baseline. Minocycline and doxycycline are\n                  not considered antibiotics when used to treat sarcoidosis.\n\n               -  Any significant finding in the patient's medical history or physical or\n                  psychiatric exam prior to or after randomization that, in the opinion of the\n                  investigator, would affect patient safety or compliance or ability to deliver\n                  the study drug according to protocol.\n\n               -  On medications that interacts with the antibiotics of the CLEAR regimen (Listed\n                  in Appendix A)\n\n               -  History of or receiving treatment for pulmonary hypertension."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "128", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02024555", 
            "org_study_id": "R01 HL117074", 
            "secondary_id": "R01HL117074-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Concomitant Levaquin, Ethambutol, Azithromycin and Rifampin", 
                "intervention_name": "Levofloxacin", 
                "intervention_type": "Drug", 
                "other_name": "Levaquin"
            }, 
            {
                "arm_group_label": "Concomitant Levaquin, Ethambutol, Azithromycin and Rifampin", 
                "intervention_name": "Ethambutol", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Concomitant Levaquin, Ethambutol, Azithromycin and Rifampin", 
                "intervention_name": "Azithromycin", 
                "intervention_type": "Drug", 
                "other_name": "Z-pack"
            }, 
            {
                "arm_group_label": "Concomitant Levaquin, Ethambutol, Azithromycin and Rifampin", 
                "intervention_name": "Rifampin", 
                "intervention_type": "Drug", 
                "other_name": "Rifadin, Rimactane"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "This will serve as a placebo to the antibiotics used in antimycobacterial therapy.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Anti-Bacterial Agents", 
                "Ethambutol", 
                "Ofloxacin", 
                "Rifampin", 
                "Azithromycin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 15, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45267"
                    }, 
                    "name": "University of Cincinnati"
                }, 
                "investigator": {
                    "last_name": "Robert Baughman, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Dan Culver, DO"
                }, 
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44195"
                    }, 
                    "name": "Cleveland Clinic"
                }, 
                "investigator": {
                    "last_name": "Dan Culver, DO", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "wonder.drake@vanderbilt.edu", 
                    "last_name": "Wonder Drake, MD", 
                    "phone": "615-322-2035"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37232"
                    }, 
                    "name": "Vanderbilt University School of Medicine"
                }, 
                "investigator": {
                    "last_name": "Wonder Drake, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Investigation of the Efficacy of Antimycobacterial Therapy on Pulmonary Sarcoidosis Phase II Randomized, Double-blind, Placebo-controlled Trial", 
        "overall_contact": {
            "email": "wonder.drake@vanderbilt.edu", 
            "last_name": "Wonder Drake, MD", 
            "phone": "615-322-2035"
        }, 
        "overall_contact_backup": {
            "email": "cisily.r.harrison@vanderbilt.edu", 
            "last_name": "Cisily Harrison", 
            "phone": "615-322-2035"
        }, 
        "overall_official": {
            "affiliation": "Vanderbilt University School of Medicine", 
            "last_name": "Wonder Drake, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Data and Safety Monitoring Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Determine the effect of CLEAR therapy versus placebo on the change in percent predicted absolute forced vital capacity (FVC) in participants with pulmonary sarcoidosis, comparing baseline with performance after completion of 16 weeks of therapy.", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 4, 8, 16 and 24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02024555"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Vanderbilt University", 
            "investigator_full_name": "Wonder Drake", 
            "investigator_title": "Associate Professor of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Radiographic improvement  in sarcoidosis lung disease by frontal chest x-ray .", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 16 weeks"
            }, 
            {
                "description": "Outcome measure if a composite", 
                "measure": "Change in 6 minute walk distance, oxygen saturation and level of dyspnea", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 4, 8 and 16 weeks"
            }, 
            {
                "description": "Outcome measure if a composite", 
                "measure": "Change in the Saint George's Respiratory Questionnaire (SGRQ; King's Sarcoidosis Questionnaire (KSQ) for the assessment of health status; The Fatigue Assessment Scale (FAS).", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 4, 8, 16 and 24 weeks"
            }, 
            {
                "measure": "Safety profile of regimen as evidenced by adverse events and abnormal lab values, tolerability and toxicity of the treatment regimen including comparison of reported adverse events and abnormal laboratory values compared to placebo.", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, 4, 8, 16 and 24 weeks"
            }, 
            {
                "measure": "Change in  FEV1", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 4, 8, 16 and 24 weeks"
            }, 
            {
                "description": "We will assess how many subjects in either arm need escalation of their standard regimen (ie increase in prednisone) during the 16 weeks.", 
                "measure": "Failure of standard Therapy", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 4, 8,  and 16 weeks"
            }
        ], 
        "source": "Vanderbilt University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Heart, Lung, and Blood Institute (NHLBI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Vanderbilt University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}